It is driven by the increasing prevalence of UCDs. The global urea cycle disorder (UCD) treatment market is projected to grow by $215.4m from 2024 to 2028, at a CAGR of 3.2%, according to Technavio.

CSPD, carbamyl phosphate synthetase deficiency; HHH, hyperornithinemia hyperammonemia homocitrullinuria syndrome ... of the newborn and urea cycle enzyme defects by clinical presentation.